Jiangsu Bioperfectus Technologies Co

Jiangsu Bioperfectus Technologies Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Jiangsu Bioperfectus Technologies Co (688399.SS) as of Oct 18, 2026 is -31.62 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 43.19 M CNY — a change of -173.21% (lower).

EBITDA

-31.62 MCNY

YoY

-173.21%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Jiangsu Bioperfectus Technologies Co is 2025 -31.62 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Jiangsu Bioperfectus Technologies Co was 2024 43.19 M CNY. It decreases by -173.21% lower compared to the previous year.

The Jiangsu Bioperfectus Technologies Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
85.99 M CNY
Jan 1, 2019
110.94 M CNY
Jan 1, 2020
982.81 M CNY
Jan 1, 2021
1.43 B CNY
Jan 1, 2022
2.21 B CNY
Jan 1, 2023
-312.07 M CNY
Jan 1, 2024
43.19 M CNY
Jan 1, 2025
-31.62 M CNY
The Jiangsu Bioperfectus Technologies Co EBITDA history
YEAREBITDAYoY
-31.62 MCNY-173.21%
43.19 MCNY-113.84%
-312.07 MCNY-114.12%
2.21 BCNY+54.98%
1.43 BCNY+45.07%
982.81 MCNY+785.88%
110.94 MCNY+29.02%
85.99 MCNY+44.38%
59.56 MCNY+339.24%
13.56 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jiangsu Bioperfectus Technologies Co Stock analysis

What does Jiangsu Bioperfectus Technologies Co do? Jiangsu Bioperfectus Technologies Co Ltd, based in Taizhou, China, operates in the Health Care sector, focusing on in vitro diagnostic reagents and testing instruments. The company develops, produces, and sells diagnostic reagents, instruments, and testing services primarily for infectious disease control, clinical testing, population screening, and prenatal/postnatal care. With 1,082 employees, it serves both domestic and international markets, having listed on the stock market in December 2019. Jiangsu Bioperfectus Technologies Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jiangsu Bioperfectus Technologies Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Jiangsu Bioperfectus Technologies Co is -31.62 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Jiangsu Bioperfectus Technologies Co changed from 43.19 M CNY to -31.62 M CNY, representing a -173.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Jiangsu Bioperfectus Technologies Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Jiangsu Bioperfectus Technologies Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Jiangsu Bioperfectus Technologies Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Jiangsu Bioperfectus Technologies Co